How immunotherapy cancer drugs affect the way the liver handles other medicines
Tests whether immunotherapy changes how the liver processes other drugs in adults with cancer.
Key facts
- Who runs it
- Indiana University
- Where
- Indianapolis, United StatesSee the site
- Trial code
- Registry title
- Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study
- Status
- Not yet recruiting
- Phase
- Early phase 1
- People taking part
- 80 people, planned
- Started
- Sept 2026
- Expected to end
- Dec 2027
- Type of study
- Interventional, 2 groups
- Treatments tested
- ICI Therapy
- Record updated
- 15 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with cancer who are starting treatment that includes an immune checkpoint inhibitor. It studies whether these drugs change how the liver processes other drugs.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Diagnosed with cancer, about to start treatment that includes an immune checkpoint inhibitor (for example atezolizumab, cemiplimab, durvalumab, ipilimumab, nivolumab, pembrolizumab, relatlimab, tremelimumab).
- Earlier treatment
- Cannot be taking systemic immunosuppressant drugs, or probe cocktail drugs and strong inhibitors or inducers of the relevant CYP enzymes or drug transporters. They can re-screen after stopping these for 7 days or more before Study Visit 1.
Main reasons for not taking part
- Pregnant or breastfeeding
- Body weight under 50 kg (110 lb) or BMI over 35, or hemoglobin under 10 g/dL
- Chronic liver or kidney disease, or abnormal liver or kidney test results
- Autoimmune disorder, such as lupus, Crohn's disease or multiple sclerosis
- Allergy to a study drug, a current infection needing treatment, or unable to take oral medication
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- ≥ 18 years old at the time of informed consent
- Diagnosed with cancer AND initiating therapy with single agent or combination therapy that includes an immune checkpoint inhibitor (e.g., atezolizumab, cemiplimab, durvalumab, ipilimumab, nivolumab, pembrolizumab, relatlimab, tremelimumab)
- Ability to provide written informed consent and HIPAA authorization
Who cannot take part
- Poor performance status that makes it unlikely the patient will complete 3 cycles of immune checkpoint inhibitor (at the treating oncologist's discretion)
- Concomitant treatment with systemic immunosuppressant drugs (see Appendix 3 for list); Note: patients may be re-screened for trial eligibility if they discontinue any exclusionary drugs for ≥7 days prior to Study Visit 1
- Concomitant treatment with a CYP/transporter probe cocktail drug or strong inhibitors, inducers, or agents that affect the pharmacokinetics of the relevant CYP enzymes or drug transporters (see Appendix 4 for list); Note: patients may be re-screened for trial eligibility if they discontinue any exclusionary drugs for ≥7 days prior to Study Visit 1
- Are unwilling/unable to avoid drugs of abuse, tobacco products or marijuana, or consuming more than 2 alcoholic drinks per day during the study
- Inability to take oral medication
- Past medical history of chronic kidney disease, signs and symptom of kidney disease (e.g., decreased urine output, swelling in feet and ankles), or estimated glomerular filtration rate <45 mL/minute/1.73 m2 BSA; Note: if a prospective patient's kidney function returns to the normal range, they can be re-screened for trial inclusion)
- Diagnosis or past medical history of autoimmune disorder, including systemic lupus erythematosus, Crohn's disease, Sjogren's syndrome, multiple sclerosis, type 1 diabetes mellitus, Behcet's disease, and ankylosing spondylitis
- History of intolerance, allergic reaction, or hypersensitivity to any of the study drugs (tizanidine, bupropion, flurbiprofen, omeprazole, dextromethorphan, midazolam, rosuvastatin)
- Current infection requiring medical treatment (note: if a prospective patient's infection resolves, they can be re-screened for trial inclusion)
- Low baseline hemoglobin, defined as <10 g/dL; Note: if a prospective patient's hemoglobin returns to the normal range, they can be re-screened for trial inclusion)
- Past medical history of chronic liver disease, signs and symptom of liver disease (e.g., jaundice, ascites), or aspartate aminotransferase >96 U/L, alanine aminotransferase > 80 IU/L, alkaline phosphatase >260 U/L, or total bilirubin > 2.6 mg/dL; Note: if a prospective patient's liver function tests return to the normal ranges, they can be re-screened for trial inclusion)
- Actively pregnant or breastfeeding
- Body weight less than 50 kg or a BMI >35
Where in United States
- Indiana University Melvin and Bren Simon Comprehensive Cancer CenterIndianapolis, United StatesContact: Ross RobinsonNot yet recruiting
About the trial
What the trial wants to find out
Immune checkpoint inhibitors (ICIs) (also called "immunotherapy") are an effective family of anti-cancer drugs, but they can cause serious side effects. Some evidence suggests these side effects might happen because ICIs interact with other drugs that you may already be taking, making those drugs work differently, or causing more side effects. The purpose of this study is to see whether ICIs impact how the liver processes other drugs. To do this, participants will be given a probe cocktail of 7 different FDA-approved drugs that are processed in different ways in the liver.
The 2 groups in the trial
- Cohort 1Treatment being tested
CYP enzyme/drug transporter probe substrates administered at two study visits: one before initiation of ICI therapy and one while on therapy.
Treatment: ICI Therapy
- Cohort 2Treatment being tested
CYP enzyme/drug transporter probe substrates administered at one study visit: during ICI therapy.
Treatment: ICI Therapy
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Assessment of Drug-Drug Interactions Between Immune Checkpoint Inhibitors and Cytochrome P450 Substrates: Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study
- Plain-language title
- How immunotherapy cancer drugs affect the way the liver handles other medicinesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Record updated
- 15 July 2026